Polygomer: The Influence of Polymeric Versus Oligomeric Enteral Feeding on Tolerance and Nutritional Status in Paediatric Intensive Care

Sponsor
Brno University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04551846
Collaborator
(none)
200
1
2
19
10.5

Study Details

Study Description

Brief Summary

Malnutrition is associated with negative impact on morbidity and mortality of critically ill patients. Therefore, in patients unable of peroral intake, the nutritional support is indicated. The preferred form of nutritional support is enteral, the more natural form, compared to parenteral. The enteral nutrition is cheaper and is associated with better outcomes and lower incidence of associated complications. The intolerance of enteral feeding is common in critically ill patients, and is associated with insufficient energy and protein intake, that could be linked with the complications such aspiration pneumonia. The optimization of enteral feeding tolerance is therefore one of the research priorities. Implementation of feeding protocols is associated with better tolerance. The enteral feeding could be administered as a oligomeric or polymeric formula. The are preliminary data from adult population pointing at better tolerance of oligomeric feeding formula.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Oligomeric enteral feeding
  • Dietary Supplement: Polymeric enteral feeding
N/A

Detailed Description

After Ethics Committee approval, all paediatric patients admitted to the paediatric intensive care unit (PICU) will underwent PICU screening. In case of eligible for inclusion in to the study, the baseline parameters a demographics will be evaluated together with the initial laboratory sampling after approval and singed the informed consent by the legal guardian of the patient. Patients will be randomized by the online randomizer to the oligomeric and polymeric enteral nutrition group.

Polymeric (control group): Patients indicated for at least 2 days of enteral nutrition by the gastric tube. The nutritional support will be initiated after initial haemodynamic stabilization (blood levels of lactate normalization, norepinephrine infusion <0,1 ug/kg/min) in the 48-hours interval from admission in form of bolus administration of polymeric formula 1ml/kg/dose. The gastric residual volume will be evaluated after 4 hours from bolus dose. In case of gastric residual volume lower than half of previously administered dose, the next dose will be doubled. In case of higher residual volume, the same amount will be administered with the metoclopramid (3 times per day). In case of persistent residual volume higher than half of initial dose in 12 hours, the erythromycin will be initiated for 3 days. The bolus enteral feeding will be administered at the predefined time 5/day (6:00, 10:00, 14:00, 18:00, 22:00). The las gastric decompression is planned ad 24:00. The aim is to reach energetic goal defined by Schofield equation.

Interventional (oligomeric group): Patients indicated for at least 2 days of enteral nutrition by the gastric tube. The nutritional support will be initiated after initial haemodynamic stabilization (blood levels of lactate normalization, norepinephrine infusion <0,1 ug/kg/min) in the 48-hours interval from admission in form of bolus administration of oligomeric formula 1ml/kg/dose. The gastric residual volume will be evaluated after 4 hours from bolus dose. In case of gastric residual volume lower than half of previously administered dose, the next dose will be doubled. In case of higher residual volume, the same amount will be administered with the metoclopramid (3 times per day). In case of persistent residual volume higher than half of initial dose in 12 hours, the erythromycin will be initiated for 3 days. The bolus enteral feeding will be administered at the predefined time 5/day (6:00, 10:00, 14:00, 18:00, 22:00). The las gastric decompression is planned ad 24:00. The aim is to reach energetic goal defined by Schofield equation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Monocentric randomized controlled trial with 2 groups: interventional (oligomeric formula) and control (polymeric)Monocentric randomized controlled trial with 2 groups: interventional (oligomeric formula) and control (polymeric)
Masking:
Single (Participant)
Masking Description:
The patients and the legal guardians will be blinded
Primary Purpose:
Treatment
Official Title:
The Influence of Polymeric Versus Oligomeric Enteral Feeding on Tolerance and Nutritional Status in Paediatric Intensive Care: Prospective Randomized Trial
Actual Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oligomeric enteral feeding group

Oligomeric enteral nutrition will be administered according to the study protocol

Dietary Supplement: Oligomeric enteral feeding
Oligomeric enteral feeding will be administered to the PICU patients
Other Names:
  • Oligomeric enteral formula
  • Active Comparator: Polymeric enteral feeding group

    Polymeric enteral nutrition will be administered according to the study protocol

    Dietary Supplement: Polymeric enteral feeding
    Polymeric enteral feeding will be administered to the PICU patients
    Other Names:
  • Polymeric enteral formula
  • Outcome Measures

    Primary Outcome Measures

    1. The amount of energy delivery at 7th day [on the 7th day after study inclusion]

      The amount of delivered energy at 7th day according to the defined energy goal by derived from Schofield equation

    2. The amount of protein delivery at 7th day [on the 7th day after study initiation]

      The amount of protein delivered at 7th day according to the defined protein delivery goal by derived from Schofield equation

    Secondary Outcome Measures

    1. The time needed to achieve the energy target [in 7 days after study initiation]

      The time needed to achieve the energy target according to the Schofield equation

    2. The time needed to achieve the protein target [in 7 days after study initiation]

      The time needed to achieve the protein target according to the Schofield equation

    3. The daily energy delivery [in 7 days after study initiation]

      The daily amount of energy delivery

    4. The daily gastric residual volume [in 7 days after study initiation]

      The daily gastric residual volume

    5. The mean gastric residual volume [in 7 days after study initiation]

      The mean gastric residual volume

    6. The time to first stool [in 7 days after study initiation]

      The time to first stool from study initiation

    7. The daily number of stool [in 7 days after study initiation]

      The daily number of stool from study initiation

    8. Nutritional parameters 1 - albumin [in 7 days after study initiation]

      albumin plasmatic levels

    9. Nutritional parameters 1 - prealbumin [in 7 days after study initiation]

      prealbumin plasmatic levels

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Month to 20 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • PICU patients indicated for nutritional support by enteral feeding (gastric or jejunal)
    Exclusion Criteria:
    • Enteral feeding contraindicated

    • Persistent haemodynamic instability

    • Informed consent not signed

    • Acute pancreatitis

    • Recent upper gastrointestinal surgery

    • Gut perforation

    • Ileus

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Brno University Hospital Brno South Moravian Region Czechia 62500

    Sponsors and Collaborators

    • Brno University Hospital

    Investigators

    • Study Chair: Petr Štourač, prof. MD., Ph.D., Faculty of medicince Masaryk University and University Hospital Brno

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Petr Štourač, MD, Clinical Professor, Brno University Hospital
    ClinicalTrials.gov Identifier:
    NCT04551846
    Other Study ID Numbers:
    • KDAR FN Brno 2020/10/2
    First Posted:
    Sep 16, 2020
    Last Update Posted:
    Jul 19, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Petr Štourač, MD, Clinical Professor, Brno University Hospital

    Study Results

    No Results Posted as of Jul 19, 2022